Concepts (82)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Neoplasms | 5 | 2025 | 174 | 1.090 |
Why?
|
| Urology | 1 | 2023 | 46 | 0.750 |
Why?
|
| Carcinoma, Renal Cell | 4 | 2025 | 114 | 0.630 |
Why?
|
| Nephroureterectomy | 1 | 2018 | 2 | 0.570 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2018 | 5 | 0.560 |
Why?
|
| Flank Pain | 1 | 2018 | 8 | 0.560 |
Why?
|
| Ureteral Neoplasms | 1 | 2018 | 10 | 0.560 |
Why?
|
| Hematuria | 1 | 2018 | 23 | 0.560 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2018 | 45 | 0.540 |
Why?
|
| Urothelium | 3 | 2020 | 22 | 0.350 |
Why?
|
| Urologic Neoplasms | 2 | 2020 | 19 | 0.310 |
Why?
|
| Ablation Techniques | 1 | 2025 | 26 | 0.230 |
Why?
|
| Radiography, Interventional | 1 | 2025 | 82 | 0.220 |
Why?
|
| Cytogenetic Analysis | 1 | 2020 | 26 | 0.160 |
Why?
|
| Catheter Ablation | 1 | 2022 | 156 | 0.160 |
Why?
|
| Urine | 1 | 2020 | 45 | 0.160 |
Why?
|
| DNA Mutational Analysis | 1 | 2020 | 198 | 0.160 |
Why?
|
| Carcinoma | 1 | 2020 | 130 | 0.150 |
Why?
|
| Kidney Pelvis | 1 | 2019 | 13 | 0.150 |
Why?
|
| Surgical Procedures, Operative | 1 | 2020 | 141 | 0.150 |
Why?
|
| Ureter | 1 | 2019 | 37 | 0.150 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2020 | 312 | 0.140 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2018 | 28 | 0.140 |
Why?
|
| Frailty | 1 | 2020 | 129 | 0.140 |
Why?
|
| Ureteroscopy | 1 | 2018 | 19 | 0.140 |
Why?
|
| Diagnosis, Differential | 2 | 2018 | 988 | 0.140 |
Why?
|
| Kidney Failure, Chronic | 1 | 2019 | 196 | 0.130 |
Why?
|
| Protein Subunits | 1 | 2018 | 169 | 0.130 |
Why?
|
| Risk-Taking | 1 | 2018 | 159 | 0.130 |
Why?
|
| Early Detection of Cancer | 1 | 2020 | 325 | 0.130 |
Why?
|
| Gene Deletion | 1 | 2018 | 311 | 0.130 |
Why?
|
| Biomarkers, Tumor | 1 | 2020 | 521 | 0.130 |
Why?
|
| Cystitis | 1 | 2016 | 10 | 0.130 |
Why?
|
| Kidney Transplantation | 1 | 2019 | 324 | 0.120 |
Why?
|
| Urinary Bladder | 1 | 2016 | 47 | 0.120 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 801 | 0.120 |
Why?
|
| Eosinophils | 1 | 2016 | 48 | 0.120 |
Why?
|
| Eosinophilia | 1 | 2016 | 35 | 0.120 |
Why?
|
| Hemangioma | 1 | 2016 | 27 | 0.120 |
Why?
|
| Kidney | 1 | 2018 | 450 | 0.120 |
Why?
|
| Lung Neoplasms | 1 | 2022 | 703 | 0.120 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2018 | 1655 | 0.100 |
Why?
|
| Liver Neoplasms | 1 | 2016 | 309 | 0.100 |
Why?
|
| Mutation | 1 | 2020 | 2657 | 0.090 |
Why?
|
| Treatment Outcome | 4 | 2025 | 5776 | 0.090 |
Why?
|
| Risk Assessment | 1 | 2018 | 2094 | 0.080 |
Why?
|
| Middle Aged | 4 | 2025 | 18210 | 0.080 |
Why?
|
| Humans | 9 | 2025 | 64956 | 0.070 |
Why?
|
| Female | 5 | 2025 | 33929 | 0.070 |
Why?
|
| Biopsy | 2 | 2019 | 454 | 0.060 |
Why?
|
| Tumor Burden | 1 | 2025 | 75 | 0.060 |
Why?
|
| Aged | 4 | 2025 | 14926 | 0.060 |
Why?
|
| Microwaves | 1 | 2022 | 14 | 0.050 |
Why?
|
| Aged, 80 and over | 2 | 2025 | 5601 | 0.050 |
Why?
|
| Urinalysis | 1 | 2020 | 37 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2020 | 67 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2020 | 94 | 0.040 |
Why?
|
| Retrospective Studies | 2 | 2025 | 6844 | 0.040 |
Why?
|
| Adult | 3 | 2025 | 17313 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 372 | 0.040 |
Why?
|
| Microscopy | 1 | 2020 | 98 | 0.040 |
Why?
|
| Allografts | 1 | 2019 | 47 | 0.040 |
Why?
|
| Male | 4 | 2025 | 30955 | 0.040 |
Why?
|
| Preoperative Care | 1 | 2020 | 198 | 0.040 |
Why?
|
| Nephrectomy | 1 | 2019 | 92 | 0.040 |
Why?
|
| Walking | 1 | 2020 | 242 | 0.030 |
Why?
|
| Time Factors | 1 | 2025 | 3758 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2020 | 1108 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2016 | 101 | 0.030 |
Why?
|
| Urologic Surgical Procedures, Male | 1 | 2016 | 51 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2019 | 1161 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2019 | 881 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 1692 | 0.030 |
Why?
|
| Risk Factors | 1 | 2025 | 5410 | 0.030 |
Why?
|
| Hydrocortisone | 1 | 2016 | 192 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2016 | 165 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2016 | 489 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 2482 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2016 | 2052 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2016 | 2240 | 0.020 |
Why?
|
| United States | 1 | 2019 | 8085 | 0.010 |
Why?
|
| Adolescent | 1 | 2016 | 6293 | 0.010 |
Why?
|